FOXM1 shows potential as a new therapeutic target in ovarian cancer, where inhibition of FOXM1 is expected to reverse or delay platinum resistance, thereby prolonging PFS and overall survival (OS) in patients. Here, FOXM1 is linked to ovarian cancer.